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EXTENDED REPORT
Minimally invasive, direct, real time measurement of drug
concentration in the anterior eye
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Aims: To evaluate a corneal contact lens which effectively turns the anterior chamber of the eye into a
cuvette, enabling the concentration of a drug to be measured using absorption spectroscopy.
Methods: A hand held contact lens incorporating optical fibres connected to a spectrograph enabled a
beam of light to be directed in, across, and out of the anterior chamber. The device was used to follow the
time course of drug concentration in the anterior chamber of rabbit (sedated) and humans, using topical
brimonidine or fluorescein (with or without local anaesthesia). Absorbance measurements were taken for a
5–25 second period, repeated every 30 minutes. Drug concentrations were compared using absorbance
peak height.
Results: Corneal absorption starts to rise rapidly at wavelengths shorter than 315 nm. The light path within
the anterior chamber is 6.9 mm (rabbit) and 5.8 mm (human), the absorbance measured also includes a
corneal component. Application of fluorescein (three drops of 2% solution) in rabbit allowed detection,
60 minutes later, of a large absorbance peak at 490 nm. In the human eye, the device could not measure
fluorescein (applied as in rabbit), but clearly detected brimonidine for 3 hours following topical
application of 0.6 mg. Modification of the device to measure fluorescence resulted in the detection of
5.3 nM fluorescein in the ex vivo rabbit eye, an increase in sensitivity of two orders of magnitude over the
absorption measurements.
Conclusion: This device has the potential to allow repeated measurements of drug concentrations in the
anterior eye provided the drug has suitable absorption or fluorescence characteristics.
D
rug absorption following topical application to the eye
is a complex process. The vast majority of the drug
applied fails to enter the eye and that proportion that
does so is likely to accumulate in the cornea and sclera or be
absorbed systemically via blood vessels in the conjunctiva
and nasal passages. Robinson1 has calculated absorption rates
(kabs) in the range of 1–5610
24 min21 with elimination rates
(kloss) of 2–5610
21 min21. To improve drug absorption
through the cornea, from where it may access lens, iris,
and ciliary body, it is necessary to decrease kloss and improve
kabs.
The ability to measure the ocular concentration of a drug
remains a fundamental requirement of any attempt to
develop an ophthalmic medication. This has often been done
in the past by paracentesis, but this technique cannot be
repeated at intervals and gives no estimate of the corneal
drug content, which is often very substantial. More informa-
tion can be gained by the harvesting of animal eyes at various
times following topical application of the drug.2 However,
this is very wasteful and laborious.
The original idea for using a scleral lens, which would
enable light to be transmitted laterally through the anterior
chamber, was proposed by Rabinovitch et al.3 4 Their object
was to determine glucose concentration in the aqueous
humour, but they did not report progress beyond the concept/
design stage. McLaren and Brubaker developed the concept
of a direct spectrophotometric scan from the aqueous
humour.5 6
Our group designed a Perspex contact lens and demon-
strated propagation of monochromatic light across the
anterior chamber of an ovine eye.7 8 Subsequently, a lens
constructed from synthetic fused silica was used to direct
monochromatic light across the anterior chamber of a rabbit
eye, in situ.9 10 We recently reported detection of brimonidine
by absorption spectroscopy in the living rabbit.11 In this paper
we report the semiquantitative detection of fluorescein in the
rabbit anterior eye and of brimonidine in the rabbit and
human eye.
MATERIALS AND METHODS
The design of the instrument aimed to turn the anterior
chamber into a spectrophotometer cuvette, using a corneal
contact lens that enabled light to pass through the anterior
chamber, perpendicular to the visual axis. This lens lay at the
front of the hand held sensor head (fig 1), which carried two
optical fibres, one coming from the light source and the other
conveying light from the ‘‘cuvette’’ to a spectrograph (for
measuring light absorption by the test compound). Also
shown in figure 1 is an alternative device where the central
port carried fluorescence light emitted from the anterior
chamber at right angles to the excitation beam (for
measuring fluorescence from the test compound). A diagram
of the light path is shown in figure 2A.
The light source for absorption spectroscopy was a xenon
arc lamp and for fluorescence measurements was an argon
ion laser (l=488 nm). The spectrograph comprised a
monochrometer (model MS127) and an open electrode
charge coupled device (CCD) array (both supplied by Oriel
Ltd, Leatherhead, UK).10 11
The spectral region available for analysis is limited by the
transmission properties of the anterior eye. The cornea and
aqueous humour of the human eye, being relatively
transparent between 300 and 1400 nm, transmit light in
the ultraviolet (UV), visible (VIS), and the near infrared
(NIP) spectral regions.12 For this study we have chosen to
analyse the UV/VIS spectral region as many of the drugs of
pharmaceutical interest have broad, easily resolvable peaks in
Abbreviations: CCD, charge coupled device; ddw, deionised and
distilled water; NIR, near infrared; UV, ultraviolet; VIS, visible
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this region. The detection range of the spectrograph was
chosen for this purpose. Alternative equipment choices would
enable the analysis of the portion of the NIR spectrum
transmitted through the eye, although a more complex
absorption peak structure would be expected.
All in vivo and ex vivo absorption spectra were generated in
a room with subdued lighting, using the following procedure.
A reference spectrum was obtained by filling the concave lens
surface of an upturned sensor head with deionised and
distilled water (ddw); the light path then passed through the
ddw and a reference spectrum ( I(l)reference) was recorded.
The lens was dried with disposable lens wipes, then coated
liberally with carbomer 980, 2% (Viscotears; Novartis
Ophthalmics, Camberley, UK) in order to cushion the cornea,
before being placed on the surface of the cornea. The light
now followed the path shown in figure 2A and a signal
spectrum ( I(l)signal ) was recorded. The absorption spectra
were then calculated:
After each measurement the concave surface of the lens
was cleaned three times with ddw, once with ethanol (70% v/
v in water), and dried.
In vivo testing was performed on both humans and rabbits
(New Zealand White). The rabbit experimental protocol was
approved by the UK Home Office. Each animal was tested no
more than four times and had a minimum of 2 weeks’ rest
period after each test. The rabbits were sedated with fentanyl,
1 mg/kg, and fluanisone, 3 mg/kg (Hypnorm; Janssen-Cilag
Ltd, High Wycombe, UK), and the cornea locally anaesthe-
tised with topical lidocaine hydrochloride (2%).
The protocol used in humans was approved by a University
of Glasgow ethics committee and adhered to the tenets of the
Declaration of Helsinki. Both of the two human male subjects
were free of eye pathology. One (32 years of age) used
lidocaine eyedrops when required, while the other (59 years;
a long term contact lens wearer) required no local anaes-
thesia.
After the above preparation, the sensor head with
Viscotears cushion was gently applied to the cornea and a
baseline absorption spectrum A(l)baseline was recorded.
Finding the optimal position for the lens took 5–25 seconds
and the recording itself took 0.5 second (each spectrum was
captured in 0.025 seconds and 20 spectra were summed) for
absorption measurements. The test drug was then topically
applied and further recordings, termed measurement spectra
(A(l)measurement) were taken at intervals of 30 minutes.
Subtraction of the baseline absorption spectrum from the
measurement spectrum yielded the difference spectrum
A(l)difference
Despite repeated application of the device, no discomfort
was experienced by the subjects. The potential for damage to
the corneal epithelium was considerably less than by
tonometry, since the area of contact for our device was much
larger than a tonometer head and it was not applied with
force required to alter the shape of the cornea, as is inevitable
in using a tonometer. Fluorescence signals were relatively
weaker and were collected over 1 second or 10 seconds.
Ex vivo measurements were performed on fresh rabbit
carcases. These were obtained approximately 30 minutes
Port for 
fluorescence
measurements
Optical
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CCD array
Xe arc
lamp
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Monochromator
Figure 1 Ocular spectrograph: the two alternative sensor heads
(incorporating the contact lens) attached to the rest of the instrumentation
via fibreoptic cables.
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Figure 2 (A) Light path through the anterior eye. When the contact lens
is placed in contact with the eye the light path traverses a total distance of
approximately 8.5 mm through the cornea and anterior chamber. The
light input and output points are optical fibres (not shown). (B) Schematic
of ex vivo eye; the aqueous humour was replaced with a range of
concentrations of fluorescein in Krebs solution.
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after death. Cannulas (23 gauge needles) were inserted
through the cornea to the anterior chamber, to allow the
aqueous humour to be easily flushed out and replaced with
test solution (fig 2B). A water manometer connected at the
inflow cannula maintained an intraocular pressure of
11 mmHg in order to preserve the curvature of the cornea.
Infusion of 3 ml of fluorescein (in Krebs solution) was
sufficient to give a constant spectroscopic signal. A series of
fluorescein solutions of various concentrations was then
tested. Absorption and emission spectra were both recorded
from the same eye.
Ocular absorption of fluorescein or brimonidine
Fluorescein solution (2%; Minims; Chauvin Ltd, Romford,
UK) was applied to human and rabbit eyes. Three drops
(approximately 25 ml per drop) were topically applied at
20 minute intervals. A baseline spectrum was taken before
fluorescein application. Brimonidine solution (30 ml of
tartrate salt, 2% w/v in isotonic saline) was topically applied
to the test eye. To avoid false positives as a result of either
drug being retained in the tear film, the test eye was briefly
irrigated with isotonic saline 5 minutes after the application
of the last drop. A series of measurement spectra were then
recorded, starting 25 minutes after application of the last
drop. Difference spectra showing only the changes caused by
application of the drug were then calculated as above.
Path length
An estimate was made of the path length of the light beam in
the rabbit eye. Comparing the absorption maxima generated
for the same range of fluorescein solutions in three separate
configurations, with each having a different path length
produced three sets of data. Configuration 1: In the ex vivo
rabbit eye, the aqueous humour was replaced by a series of
increasing concentrations of fluorescein (0, 1, 3, 10, 30 mM).
An absorption spectrum was taken at each concentration.
Configuration 2: The sensor head was held with its concave
side upwards and the hollow was filled with the same five
solutions and absorption spectra taken for each. Configuration
3: absorption spectra were measured for the five solutions
using a spectrometer and cuvettes with a 10 mm light path.
For each of the three sets of data the spectrum obtained for
the Krebs solution alone was subtracted from each of the
other four spectra to give a series of spectra with absorption
peaks at 490 nm. Plots of these peak heights versus
fluorescein concentrations produced three straight lines each
with a different gradient. Using the Beer-Lambert law and
the fact that the path length is known for the third set of
measurements enables the path length to be determined for
the first two. The Beer Lambert law is:
where A = absorption, e = molar absorption coefficient, c
= concentration and l = path length.
RESULTS
Absorption spectroscopy: corneal UV cut off for rabbit
and human
Typical baseline absorption spectra for human and rabbit eyes
are shown in figure 3. Both curves show an effective cut off in
transmission below 300 nm.
Path length
In the ex vivo rabbit eye (configuration 1) we assumed that
the cornea did not take up any fluorescein in the brief period
(,90 seconds) between infusion and recording the spectrum.
This record gave a path length of 6.9 mm within the anterior
chamber. Configuration 2 gave the combined path length
through the tear film, cornea, and anterior chamber of
8.6 mm. Using the geometry shown in figure 2 and the
reported rabbit peripheral corneal thickness of 0.4 mm,13 14
we calculated the ‘‘tear film’’ (largely Viscotears) thickness to
be 0.2 mm (see table 1). Assuming the total path length was
identical in both rabbit and humans and a peripheral corneal
thickness of 0.67 mm,15 equivalent values were calculated for
humans (table 1).
Absorption spectroscopy: fluorescein
Difference spectra following application of fluorescein (2%)
in rabbit eyes all showed an absorption peak at 490 nm
(fig 4), indicating that this compound enters the cornea in
this species. The path of the light beam was clearly visible as
a green track, both at the points where it crossed the cornea
and as it traversed the anterior chamber. In human eyes after
the application of the fluorescein (2%), all measurement
spectra were similar to baseline spectra, indicating little
penetration of fluorescein across the cornea.
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Figure 3 Typical absorption spectra for the anterior chamber of human
and rabbit.
Table 1 Calculated path lengths (mm) in the rabbit and human eye
Path length (mm)
Total
Aqueous
humour Cornea
Tear film
(including Viscotears)
Rabbit 8.6 6.9 1.5 0.2
Human 8.6 5.8 2.4 0.4
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Figure 4 Absorption change after the application of fluorescein to the
in vivo rabbit eye.
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Absorption spectroscopy: brimonidine in human and
rabbit eyes
Following the application of brimonidine (0.6 mg) in
volunteers, the difference spectrum in each eye showed a
peak at 320 nm. One of these spectra is shown in figure 5.
Using equation (3) and the total path length (table 1), the
concentration of brimonidine in the combined cornea and
anterior chamber was calculated (fig 6).
One (0.6 mg), two (1.2 mg), or three (1.8 mg) drops of
brimonidine, spaced at 20 minute intervals, were applied to
rabbit eyes and concentrations were calculated from absorp-
tion spectra. Figure 7 shows the time course of brimonidine
concentration in two eyes after the application of 1.2 mg
brimonidine. The dose dependence of concentration is shown
in figure 8.
Fluorescence spectroscopy: ex vivo rabbit
Using the sensor head with fluorescence detection, spectra
were recorded over various times. Using a 1 second collection
time it was possible to obtain clearly resolvable fluorescence
spectra at a fluorescein concentration of 53 nM. Using a
10 second collection time spectra were obtained for concen-
trations as low as 5.3 nM; one of these is shown in figure 9.
DISCUSSION
Details of the in vivo light absorptive properties of the
anterior human and rabbit eye are useful for many
applications; here it provides us with a baseline to which
subsequent measurements can be compared. To our knowl-
edge this is the first demonstration of an instrument that is
capable of performing in situ absorption spectroscopy
measurements of the anterior human eye. The absorption
spectrum in the cornea shows a generally featureless increase
in absorption with decreasing wavelength with a cut off in
transmission at approximately 300 nm in both humans and
rabbit. Our data (fig 3) are consistent with reported ex
vivo12 16 and in vivo studies.6 In our experiments, the cornea
and aqueous humour of the rabbit were found to transmit
significantly more UV and blue wavelength than the human
eye. This may be exaggerated by the longer corneal
component for the path length in human eyes. However,
even normalising for this factor, there remains a difference
between human and rabbit absorption curves.
Topical fluorescein has been detected previously in the
rabbit aqueous and cornea.17 Poor absorption of topical
fluorescein in humans has been noted before. Tonjum and
Green18 resorted to iontophoresis to achieve measurable
corneal penetration of fluorescein. In humans, blinking and
reflex tearing remove an applied drug so quickly that even
within 20 seconds of administration the residual drug has
dropped to 20% or less of the original tear film content.19
Hence, though the device was able to detect fluorescein in the
rabbit, the sensitivity was insufficient to detect the very small
fraction remaining in the human tear film.
The absorption spectrum in figure 5 and the time course in
figure 6 demonstrate that using our technique, it is clearly
possible to detect the presence and monitor the time course
of a topically applied drug in the in vivo human eye. The
minimally invasive nature of the measurement should enable
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Figure 5 Absorption change 25 minutes after the topical application of
brimonidine to an in vivo human eye.
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Figure 6 Time course of spectroscopically measured brimonidine
concentration in the human anterior eye after topical application of 30 ml
of brimonidine (2%).
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Figure 7 Time course for brimonidine concentration in the anterior
rabbit eye; 30 ml of brimonidine (2%) was topically applied twice with a
20 minute interval.
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Figure 8 Dose dependence of brimonidine concentration in the
anterior rabbit eye. One (0.6 mg), two (1.2 mg), or three (1.8 mg)
drops of brimonidine (2% in isotonic saline) were topically applied with a
20 minute interval between drops. All measurements were taken
25 minutes after application of the last drop.
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Figure 9 Fluorescence peak for 5.3 nM fluorescein in ex vivo rabbit
eye. The fluorescence peak is the broad peak at 515 nm. The peak at
488 nm is scattered light from the excitation beam.
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application to a wide range of situations. To be clinically
useful the technique needs to have the sensitivity to detect
therapeutic drug concentrations. While the results described
for brimonidine in humans were measured after application
of 10 times the standard therapeutic dose,20 the measured
brimonidine concentration did not fall below 60 mM in the
3 hours following application; this is 20 times greater than
the 3 mM brimonidine detection limit.10 Determination of the
time course of absorption following a clinical dose of
brimonidine should be possible with only a small increase
in instrument sensitivity by incorporating a continuous
reference sample, changing what is currently a single beam
system into a double beam system.
The data shown represent light absorption by brimonidine
in cornea and aqueous humour combined. Although the
corneal segment constitutes only 18% of the total light path,
the cornea clearly contains most of the measured brimoni-
dine, at least in the early stages of absorption. Absorption
kinetics of radiolabelled brimonidine in the rabbit indicate
that the ratio of corneal to aqueous concentrations is
approximately 15:1 at 20 minutes following topical admin-
istration.2 If we apply this ratio to the present data recorded
25 minutes following application of 0.6 mg brimonidine, the
cornea would account for 77% of the total measured
absorption. Therefore, at this 25 minute time point the
brimonidine concentrations in cornea and aqueous were
approximately 100 mM and 6.7 mM, respectively. The cornea
serves as a substantial depot for topically absorbed drugs.
With continual loss of drug in the aqueous humour,
concentrations in cornea are likely to remain higher than
aqueous levels until eventually they cease to be measurable.21
The detection of 5.3 nM fluorescein via fluorescence
expands the sensitivity of the technique by two orders of
magnitude from our previously reported detection limit of
0.3 mM fluorescein, obtained using absorption spectroscopy.10
While regionally specific drug concentrations are interesting,
repeated non-invasive estimation of total drug in cornea and
aqueous is useful since the aqueous bathes all the structures
of the anterior eye. The fact that our device can give repeated
measurements without trauma in the same subject, in
animals or in humans, makes it potentially very useful in
the development of ocular formulations and of novel
methods of drug delivery.
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